Amgen Inc. (AMGN) Position Increased by Jacobs & Co. CA
Jacobs & Co. CA increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.1% during the third quarter, Holdings Channel reports. The institutional investor owned 38,586 shares of the medical research company’s stock after buying an additional 803 shares during the period. Amgen accounts for approximately 1.4% of Jacobs & Co. CA’s portfolio, making the stock its 29th largest position. Jacobs & Co. CA’s holdings in Amgen were worth $6,436,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the stock. Squarepoint Ops LLC increased its stake in shares of Amgen by 298.1% in the first quarter. Squarepoint Ops LLC now owns 10,135 shares of the medical research company’s stock valued at $1,520,000 after buying an additional 7,589 shares in the last quarter. Summit Financial Wealth Advisors LLC bought a new stake in shares of Amgen during the second quarter valued at approximately $355,000. BNP Paribas Arbitrage SA increased its stake in shares of Amgen by 23.2% in the second quarter. BNP Paribas Arbitrage SA now owns 1,175,040 shares of the medical research company’s stock valued at $178,782,000 after buying an additional 221,118 shares in the last quarter. First Financial Bank N.A. Trust Division increased its stake in shares of Amgen by 1.0% in the second quarter. First Financial Bank N.A. Trust Division now owns 1,884 shares of the medical research company’s stock valued at $287,000 after buying an additional 18 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its stake in shares of Amgen by 83.3% in the second quarter. Integrated Investment Consultants LLC now owns 4,841 shares of the medical research company’s stock valued at $737,000 after buying an additional 2,200 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded down 0.86% during midday trading on Wednesday, reaching $144.74. The company had a trading volume of 2,593,385 shares. The firm has a 50-day moving average of $151.01 and a 200-day moving average of $160.49. The stock has a market cap of $107.68 billion, a P/E ratio of 14.49 and a beta of 1.15. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $176.85.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.23. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.73 billion. Amgen had a return on equity of 29.27% and a net margin of 33.63%. The business’s revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.72 earnings per share. On average, equities analysts expect that Amgen Inc. will post $11.56 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be issued a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.74%. The ex-dividend date is Monday, November 14th. Amgen’s dividend payout ratio is presently 39.92%.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Financial Market News and is the propert of of Financial Market News. If you are reading this report on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright laws. The legal version of this report can be viewed at http://www.financial-market-news.com/amgen-inc-amgn-position-increased-by-jacobs-co-ca/1210975/.
Several research analysts recently weighed in on the company. Citigroup Inc. dropped their price target on Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 28th. Leerink Swann reissued a “hold” rating and set a $193.00 price target on shares of Amgen in a research report on Sunday, September 11th. Argus reissued a “buy” rating and set a $195.00 price target (up from $185.00) on shares of Amgen in a research report on Friday, August 5th. Jefferies Group reissued a “buy” rating and set a $198.00 price target on shares of Amgen in a research report on Tuesday, August 23rd. Finally, Gabelli began coverage on Amgen in a research report on Friday, August 26th. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. Amgen presently has a consensus rating of “Buy” and a consensus price target of $182.04.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.